
Neuropathix: An American biopharmaceutical firm specializing in R&D of pain management therapies.
Neuropathix, Inc. is a biopharmaceutical company founded by Dean Petkanas and Thoma Kikis, headquartered in Doylestown, Pennsylvania. The company is dedicated to the research and development of next-generation therapeutics focused on pain management and neuroprotection. Neuropathix aims to address significant unmet medical needs by targeting inflammation through its innovative drug pipeline. Their products and services are designed to provide breakthrough treatments for patients suffering from chronic pain and neurodegenerative conditions.
Notable figures associated with Neuropathix include its founders, Dean Petkanas and Thoma Kikis. The company has achieved significant milestones, including securing patents (US 9611213, US 10004722) and receiving grant awards from the NIH-NINDS. Neuropathix's lead drug candidate, KLS-13019, has shown promising preclinical results, positioning the company as a key player in the biopharmaceutical industry. Their impact is marked by their commitment to advancing pain management therapies and contributing to the broader field of neuroprotective treatments.

NeuroTherapeutics Pharma

Neurolixis
neurolixis.com

Neuraly
neuralymed.com

NeuroTherapia
neurotherapia.com

Neuropore Therapies
neuropore.com

Neurana Pharmaceuticals
neuranapharma.com

NeurOp

Neurovia

Pharmatrophix
pharmatrophix.com

Neuros Medical
neurosmedical.com

Kannalife Sciences
kannalife.com

Nerx Biosciences

Neuraptive Therapeutics
neuraptive.com

Aptinyx
aptinyx.com

Neurodon
neurodon.net
Companies similar to Neuropathix include NeuroTherapeutics Pharma, Neurolixis, Neuraly and NeuroTherapia.
Neuropathix was founded in 2010.
Neuropathix's headquarters is located in Doylestown, PA, US.
Neuropathix has 3 employees as of Feb 5, 2024.